BIOMAT Database Logo BIOMAT Database Logo

Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 1997

G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Department of Medicine, Stanford University Medical Center, CA, USA.

Myeloablative therapy followed by allogeneic bone marrow transplantation (BMT) has proven to be curative therapy in patients with hematologic malignancies. Relapse, however, remains a major cause of treatment failure for patients with advanced disease. During the past 15 years, we have gained considerable experience with the combination of fractionated total-body irradiation (FTBI) and etoposide followed by allogeneic BMT for hematologic malignancies. In an attempt to decrease post-transplant relapse rates, 67 patients under the age of 50 years with high-risk or advanced-stage hematological malignancies received an intensified regimen of FTBI and etoposide plus cyclophosphamide followed by BMT from a genotypically-matched related donor. The regimen consisted of 1320 cGy of FTBI in 11 fractions, 60 mg/kg of etoposide (VP-16), and 60 mg/kg of cyclophosphamide (CY). Fifty-three patients received cyclosporine and prednisone for graft-vs.-host disease (GVHD) prophylaxis and 14 patients received cyclosporine, methotrexate, and prednisone. Diagnosis at BMT included 45 patients with acute leukemia, 7 patients with chronic leukemia, and 15 patients with high-grade non-Hodgkin's lymphoma (NHL). Actuarial disease-free survival (DFS) at 3 years was 42% +/- 12% for the entire group with a median follow-up of 50 months (range 20-74) for 28 patients who remain alive in continued complete remission (CR). Actuarial 3-year-DFS was 38% +/- 14% in 52 patients with acute or chronic leukemia and 60% +/- 25% in 15 patients with NHL with relapse rates of 45% +/- 16% and 21% +/- 11%, respectively. DFS at 3 years was 40% +/- 18% in 32 patients with acute leukemia in 1st relapse or 2nd CR or chronic myelogenous leukemia in accelerated phase, and was 32% +/- 22% in 20 patients with more advanced disease. Regimen related mortality occurred in 9 patients (4, veno-occlusive disease of the liver; 2, multi-organ failure; 1, diffuse alveolar hemorrhage; 1, central nervous system (CNS) hemorrhage; 1, adult respiratory distress syndrome (ARDS). The combination of FTBI, etoposide, and cyclophosphamide followed by allogeneic BMT is an effective and relatively well-tolerated regimen for patients with advanced hematologic malignancies. The role for this regimen should be further defined by prospective clinical trials.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
September 1992, American journal of hematology,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
October 2004, Clinical transplantation,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
September 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
March 2000, Bone marrow transplantation,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
July 1992, Bone marrow transplantation,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.
November 1988, Blood,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
September 1989, Bone marrow transplantation,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Fractionated total body irradiation and allogeneic bone marrow transplantation for standard risk leukemia.
December 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
January 1995, Bone marrow transplantation,
G D Long, and M D Amylon, and K E Stockerl-Goldstein, and R S Negrin, and N J Chao, and W W Hu, and A P Nademanee, and D S Snyder, and R T Hoppe, and N Vora, and R Wong, and J Niland, and V L Reichardt, and S J Forman, and K G Blume
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
August 1997, Bone marrow transplantation,
Copied contents to your clipboard!